Latest Trials Latest NewsFAQ

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Efficacy and Safety of Varenicline in Smokers With Cardiovascular Disease Who Wish to Quit Smoking

Phase 3

Completed

Conditions: Smoking Cessation

Interventions: Drug: placebo
Drug: Varenicline

First Posted Date: 2006-01-27

Last Posted Date: 2017-04-05

Lead Sponsor: Pfizer

Target Recruit Count: 714

Registration Number: NCT00282984

Locations: 🇬🇧
Pfizer Investigational Site, Paisley, United Kingdom

A Clinical Trial Assessing The Impact Of Inhaled Insulin On Glucose Control In Patients With Type 2 Diabetes Mellitus

Phase 3

Terminated

Conditions: Diabetes Mellitus Type 2

Interventions: Drug: Inhaled Insulin (Exubera)
Other: Standard of Care

First Posted Date: 2006-01-27

Last Posted Date: 2019-04-02

Lead Sponsor: Pfizer

Target Recruit Count: 354

Registration Number: NCT00282971

Locations: 🇨🇦
Gain Medical Center, Coquitlam, British Columbia, Canada
🇨🇦
Orillia Soldier's Memorial Hospital, Orillia, Ontario, Canada
🇨🇦
Maritime Research Center, Bathurst, New Brunswick, Canada

and more 60 locations

Beta Cell Function Tests Over Time In Patients With T2dm Randomized To Metformin Or Rosiglitazone

Not Applicable

Terminated

Conditions: Type 2 Diabetes Mellitus

First Posted Date: 2006-01-27

Last Posted Date: 2008-10-13

Lead Sponsor: Pfizer

Target Recruit Count: 29

Registration Number: NCT00282945

Locations: 🇮🇱
Pfizer Investigational Site, Jerusalem, Israel

Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer

Phase 2

Completed

Conditions: Kidney Neoplasms
Carcinoma, Renal Cell

Interventions: Drug: AG-013736 (axitinib)

First Posted Date: 2006-01-25

Last Posted Date: 2012-07-31

Lead Sponsor: Pfizer

Target Recruit Count: 62

Registration Number: NCT00282048

Locations: 🇺🇸
Pfizer Investigational Site, Madison, Wisconsin, United States

The Aim is to Estimate the Total Amount of Insulin-producing Cells in the Pancreas by MRI.

Not Applicable

Terminated

Conditions: Diabetes Mellitus

First Posted Date: 2006-01-20

Last Posted Date: 2009-08-07

Lead Sponsor: Pfizer

Target Recruit Count: 29

Registration Number: NCT00280085

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

Exemestane As Treatment In Adjuvant For Post-Menopausal Patients With Non-Metastatic Breast Cancer

Phase 3

Completed

Conditions: Breast Neoplasms

Interventions: Drug: exemestane
Drug: tamoxifen

First Posted Date: 2006-01-19

Last Posted Date: 2011-12-23

Lead Sponsor: Pfizer

Target Recruit Count: 9779

Registration Number: NCT00279448

Locations: 🇫🇷
Pfizer Investigational Site, Vannes, France

CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Non-Responder (Null And Partial Responder) Hepatitis C Virus (HCV) Genotype 1 Infected Subjects

Phase 2

Completed

Conditions: Hepatitis, Chronic Active

Interventions: Drug: Control
Drug: CPG10101

First Posted Date: 2006-01-16

Last Posted Date: 2017-03-08

Lead Sponsor: Pfizer

Target Recruit Count: 113

Registration Number: NCT00277238

Locations: 🇺🇸
Pfizer Investigational Site, Richmond, Virginia, United States

Study Evaluating the Safety, Tolerability, and Efficacy of Lecozotan SR in Outpatients With Alzheimer's Disease

Phase 2

Completed

Conditions: Alzheimer Disease

Interventions: Drug: lecozotan SR (SRA-333)

First Posted Date: 2006-01-16

Last Posted Date: 2020-07-07

Lead Sponsor: Pfizer

Target Recruit Count: 250

Registration Number: NCT00277810

A Research Study to Compare the Treatments of a Combination of Elzasonan With Zoloft, to Zoloft Alone, or Placebo in People With Major Depressive Disorder (MDD)

Phase 2

Completed

Conditions: Depressive Disorder, Major

First Posted Date: 2006-01-11

Last Posted Date: 2008-11-02

Lead Sponsor: Pfizer

Target Recruit Count: 262

Registration Number: NCT00275197

Locations: 🇷🇺
Pfizer Investigational Site, St. Petersburg, Russian Federation

A Study Of Different Doses Of TBC3711 In Patients With Uncontrolled High Blood Pressure Already Taking Medications For High Blood Pressure.

Phase 2

Terminated

Conditions: Resistant Hypertension

Interventions: Drug: TBC3711
Drug: Placebo

First Posted Date: 2006-01-09

Last Posted Date: 2013-03-05

Lead Sponsor: Pfizer

Target Recruit Count: 60

Registration Number: NCT00272961

Locations: 🇺🇸
Pfizer Investigational Site, Seattle, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy